Andy
Unfollow Follow Andy
Interview with Bydureon Development team
Rajesh Kumar (Alkermes) shares how Bydureon - the first once weekly GLP1 analogue - was developed.
Interview with the Rajesh Kumar (Alkermes) on the Development of Bydureon™ controlledreleasesociety.org
Bydureon (exenatide extended-release for injectable suspension) is now approved by the U.S. FDA and in various territories outside the United States. For many people, trying to maintain the appropriate blood sugar (glucose) levels day after day can be frustratingly difficult. Other formulations of GLP-1 receptor agonists require twice-daily or once-daily administration. In contrast, Bydureon only
posted 8 months ago
Yogita Pandit Satam 8 months ago • Edit • Yogita Pandit likes this. »
x wangshouzou wangshouzou
Send me an email for each new comment.
See more »
Like
CommentFollowMore Share Link
Flag as PromotionFlag as JobFlag as InappropriateReply Privately